Non-response to short-term ketamine use for treatment-resistant depression
Pharmacological Reports · 2025
DOI: 10.1007/s43440-025-00730-9 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pharmacological Reports, 2025. Verfasst von Michał Walaszek und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, ul. Smoluchowskiego 17, Gdańsk, 80-214, Poland. michal.walaszek@gumed.ed…. Hauptthemen laut MEDLINE: Ketamine, Depressive Disorder, Treatment-Resistant, Major Depressive Disorder, Antidepressive Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gdański Uniwersytet Medyczny.
Themen: Depression
Abstract (Originalsprache)
Background
Ketamine is currently gaining attention as a rapid-acting antidepressant for treatment-resistant depression (TRD). However, many patients fail to respond, and limited data exist on predictors of non-response. This study aims to characterize the sociodemographic and clinical features associated with non-response to ketamine among TRD patients.
Methods
This is a post-hoc analysis of a naturalistic observational study, which enrolled 40 inpatients with treatment-resistant major depressive disorder and analyzed sociodemographic and clinical features in responders and non-responders stratified per Montgomery-Åsberg Depression Rating Scale (MADRS) during short-term ketamine administration (intravenous dosage: 0,5 mg/kg and orally: 2.0 or 2.5 mg/kg) that comprise over 4 weeks.
Results
In this study, 30 patients (75%) were classified as non-responders. No significant differences were detected among sociodemographic and clinical features beyond the history of substance use disorder (SUD) – only 53.3% of non-responders reported prior SUD (vs. 100%; p = 0.0075) and a lower number of psychiatric comorbidities ( p = 0.0381).
Conclusion
This study highlights key characteristics of TRD non-responders to ketamine, including lower rates of SUD and fewer psychiatric comorbidities. These findings suggest that a higher burden of traditional TRD risk factors may not limit ketamine efficacy and could even enhance response compared to “pure” major depressive disorder. Identifying potential non-responders early can optimize treatment decisions, reduce ineffective exposure, and guide future research on improving TRD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, ul. Smoluchowskiego 17, Gdańsk, 80-214, Poland. michal.walaszek@gumed.edu.pl.
- Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, ul. Smoluchowskiego 17, Gdańsk, 80-214, Poland.
- Department of Algorithms and System Modeling, Gdansk University of Technology, Gdańsk, Poland.
- Laboratory of Translational Oncology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland.
- Center of Biostatistics and Bioinformatics, Medical University of Gdańsk, Gdańsk, Poland.
Förderung
- Gdański Uniwersytet Medyczny
Zitieren
APA
Walaszek, M., Cubała, W. J., Kachlik, Z., Pastuszak, M., Pastuszak, K., & Kwaśny, A. (2025). Non-response to short-term ketamine use for treatment-resistant depression. Pharmacological Reports. https://doi.org/10.1007/s43440-025-00730-9
Vancouver
Walaszek M, Cubała WJ, Kachlik Z, Pastuszak M, Pastuszak K, Kwaśny A. Non-response to short-term ketamine use for treatment-resistant depression. Pharmacological Reports. 2025. doi:10.1007/s43440-025-00730-9
BibTeX
@article{Walaszek2025,
author = {Walaszek, Michał and Cubała, Wiesław Jerzy and Kachlik, Zofia and Pastuszak, Michał and Pastuszak, Krzysztof and Kwaśny, Aleksander},
title = {Non-response to short-term ketamine use for treatment-resistant depression},
journal = {Pharmacological Reports},
year = {2025},
doi = {10.1007/s43440-025-00730-9}
}
EUVIMED